The present disclosure relates to chemical compounds and their use in
human therapy. In a specific embodiment, compounds of Formula (I) or an
isomer, a pharmaceutically acceptable salt or solvate thereof or a
pharmaceutically acceptable formulation comprising said compounds useful
for the treatment or prevention of conditions mediated by tachykinins
and/or selective inhibition of serotonin reuptake transporter protein.
The compounds act as dual NK-1 antagonists and selective serotonin
reuptake inhibitors.